AUTL
AUTL clinical trials: Autolus Therapeutics plc
Every trial on ClinicalTrials.gov where Autolus Therapeutics plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 11
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AUTL on the catalyst calendar · AUTL registry changes
- Primary completion Nov 2027Sponsor estimatePhase 1NCT06173518A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B...Autolus Limited · Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2NCT07053800Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)Autolus Limited · Lupus NephritisRecruitingAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2029Sponsor estimatePhase 1NCT07139743Obe-cel in Refractory Progressive Forms of Multiple SclerosisAutolus Limited · Progressive Multiple SclerosisRecruitingAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2043Sponsor estimatePhase 2NCT03628612Long-term Follow-up of Patients Treated With Genetically Modified Autologous T CellsAutolus Limited · Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell TherapyEnrolling by invitationAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1NCT06333483Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusAutolus Limited · Systemic Lupus ErythematosusActive, not recruitingAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2029Sponsor estimatePhase 1/Phase 2NCT04404660A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Autolus Limited · Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaActive, not recruitingAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06799221Expanded Access Program for OOS Obe-celAutolus Limited · Lymphoblastic Leukemia, Acute, AdultAvailableAUTLLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2024ActualPhase 1/Phase 2NCT03590574Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell LymphomaAutolus Limited · T Cell Non-Hodgkin LymphomaTerminatedAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2023ActualPhase 1/Phase 2NCT03287817Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell LymphomaAutolus Limited · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2020ActualPhase 1/Phase 2NCT03289455CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)Autolus Limited · B Acute Lymphoblastic LeukemiaCompletedAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2019ActualPhase 1/Phase 2NCT03287804APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple MyelomaAutolus Limited · Multiple MyelomaTerminatedAUTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2029Sponsor estimatePhase 2NCT07400029A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic LeukemiaMemorial Sloan Kettering Cancer Center · Acute Lymphoblastic LeukemiaRecruitingAUTLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2028Sponsor estimatePhase 2NCT07053059Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed...M.D. Anderson Cancer Center · Acute Lymphocytic Leukemia (ALL)RecruitingAUTLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner